Eupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Lowered to Sell at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

A number of other analysts have also issued reports on the stock. Leede Financial raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ:EPRX opened at $6.20 on Friday. The firm has a market capitalization of $222.95 million, a PE ratio of -7.13 and a beta of 1.47. The business has a 50 day simple moving average of $5.91 and a two-hundred day simple moving average of $5.22. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $7.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. Equities research analysts expect that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Quadrature Capital Ltd bought a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $61,000. TCI Wealth Advisors Inc. purchased a new position in Eupraxia Pharmaceuticals during the third quarter valued at approximately $65,000. Integrated Wealth Concepts LLC bought a new position in Eupraxia Pharmaceuticals in the third quarter worth approximately $71,000. Bank of America Corp DE lifted its holdings in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Eupraxia Pharmaceuticals by 593.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.